Table 1

 Patient data, psoriasis diagnosis, type of TNFα antagonist, interval between last TNFα antagonist and onset/exacerbation of psoriasis

CaseRFAnti-CCPTNFα antagonists*Latency‡ (months)Psoriasis typeHistologyNew onsetFamily§
*In order of administration; †TNFα antagonist with onset or exacerbation of psoriasis; ‡latency: interval between first administration of the last TNFα antagonist and onset/exacerbation of psoriasis; §family member with psoriasis.
RF, rheumatoid factor, anti-CCP, anti-cyclic citrullinated peptide antibodies; ADA, adalimumab; ETA, etanercept; INF, infliximab.
1++ADA†, ETA, INF, ETA14VulgarisYesYesNo
2++ETA†1PustulosaYesExacerbationNo
3++ETA, ADA†(4 days)VulgarisYesYesNo
4+NAINF†2VulgarisNoExacerbationSister
5++ADA†5PustulosaYesYesBrother
6Neg.NAETA, INF†, ETA, ADA8PustulosaNoExacerbationNo
7+NAETA†1VulgarisNoExacerbationNo
8+NAETA†2VulgarisNoYesNo
9+NAADA†, INF11VulgarisNoYesNo